SunTrust Upgrades Amarin Corporation (AMRN) to Buy
Get Alerts AMRN Hot Sheet
Rating Summary:
6 Buy, 12 Hold, 2 Sell
Rating Trend: Up
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 14
Join SI Premium – FREE
(Updated - February 18, 2015 10:29 AM EST)
SunTrust Robinson Humphrey upgraded Amarin Corporation (NASDAQ: AMRN) from Neutral to Buy with a price target of $6.00 (from $2.00), suggesting 408% upside from yesterday's close.
In the report, analyst John Boris cited their above consensus 2020 estimates of $558M/$1.27, which compare favorably to the Street consensus of $496M/$0.78. He also noted a compelling risk/reward at current levels.
Boris noted Vascepa's superior profile, competitive pricing vs. GSK's Lovaza and TEVA/Par's generics, expanding Tier 2 coverage, and free call options on ANCHOR (36M patients) and REDUCE-IT (34M patients) label expansion and ex-US strategic options for Vascepa.
On pricing, the analyst notes Vascepa is priced at a 21% discount to GSK's Lovaza and just an 8-24% premium to generics. He also said Vascepa Tier 2 coverage should expand in 2015 as Lovaza is removed.
On ANCHOR, the analyst notes that the FDA is seriously delinquent under PDUFA since it did not issue a decision on the ANCHOR sNDA that was filed in Dec. 2013. "In the wake of the favorable IMPROVE-IT results from MRK, we would expect the FDA to either issue a CRL (high probability assumed) and/or allow the ANCHOR data into the Vascepa label (low probability)," he commented.
The analyst concludes, saying the risk/reward on the stock is "skewed heavily" toward their $6 base case price target. Meanwhile a bear case is just $1, while an bull case is $17.
For an analyst ratings summary and ratings history on Amarin Corporation click here. For more ratings news on Amarin Corporation click here.
Shares of Amarin Corporation closed at $1.18 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event
- Loop Capital Upgrades Sea Ltd. (SE) to Buy, 'shift to sustained profitable growth is finally underway'
- JPMorgan Upgrades Doximity Inc (DOCS) to Neutral
Create E-mail Alert Related Categories
Hot Upgrades, UpgradesRelated Entities
SunTrust Robinson HumphreySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!